Regeneron CEO says Amgen not putting patients first in patent dispute

A federal judge last week handed Regeneron and its partner Sanofi a stunning setback by banning sales of their LDL-lowering medicine Praluent, finding it infringed patents held by Amgen on its Repatha cholesterol drug. Regeneron and Sanofi were given 30 days before the ban takes effect to give them time to appeal.

Go here to read the rest: 
Regeneron CEO says Amgen not putting patients first in patent dispute